IGFBP2 and cancer: ANXA1 was also found to be correlated with IGFBP2 (insulin-like growth factor-binding protein 2), a circulating biomarker for cancer diagnosis and a potential immunotherapeutic target, also belonging to the gene signature identified by Model II.